title: [A clinical study of acute lymphoblastic leukemia in adolescents: a single center experience].
abstract: OBJECTIVE
  To explore the clinical and laboratory characteristics, treatment, prognostic factors of acute lymphoblastic leukemia (ALL) in adolescents.
  
  
  METHODS
  Adolescents de novo ALL patients in Blood Disease Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences from September 1999 to September 2013 were enrolled in this study. Clinical data, therapeutic effect and prognostic factors were retrospectively analyzed.
  
  
  RESULTS
  Of all 94 patients, 91 patients were treated in our center. The overall complete remission (CR) rate was 96.7% (88/91), CR rate after one cycle was 91.2%(83/91). The median follow-up time was 18 months. In all patients, the 6-year anticipated overall survival (OS) rate and disease free survival (DFS) rate were (47.6 ± 6.7)% and (45.4 ± 6.0)% respectively. In standard risk ALL patients , 6-year anticipated OS rate and DFS rate were (65.7 ± 8.1)% and (65.3 ± 7.4)%. Hyperleukocytosis (white blood cell count ≥30 × 10(9)/L in B-ALL; ≥100 × 10(9)/L in T-ALL), Ph(+) , MLL(+) , hypodiploid were risk factors associated with poor clinical outcome.
  
  
  CONCLUSIONS
  The therapeutic effect and clinical outcome in adolescents with ALL are relatively favorable, especially in standard risk group. In high risk ALL patients, allogeneic hematopoietic stem cell transplantation may improve therapeutic efficacy.
authors.affiliation: Institute of Hematology and Blood Disease Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences , Tianjin 300020, China.
authors.forename: Kaiqi
authors.initials: K
authors.lastname: Liu
authors.forename: Xingli
authors.initials: X
authors.lastname: Zhao
authors.forename: Hui
authors.initials: H
authors.lastname: Wei
authors.forename: Dong
authors.initials: D
authors.lastname: Lin
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Chunlin
authors.initials: C
authors.lastname: Zhou
authors.forename: Bingcheng
authors.initials: B
authors.lastname: Liu
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Huijun
authors.initials: H
authors.lastname: Wang
authors.forename: Chengwen
authors.initials: C
authors.lastname: Li
authors.forename: Qinghua
authors.initials: Q
authors.lastname: Li
authors.forename: Benfa
authors.initials: B
authors.lastname: Gong
authors.forename: Shuning
authors.initials: S
authors.lastname: Wei
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Yuntao
authors.initials: Y
authors.lastname: Liu
authors.forename: Xiaoyuan
authors.initials: X
authors.lastname: Gong
authors.forename: Yingchang
authors.initials: Y
authors.lastname: Mi
authors.forename: Jianxing
authors.initials: J
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D002681:China; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007958:Leukocyte Count; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000453:epidemiology*; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate